Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Long-Term Debt Repayments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.0 million through Dec 2025, up 6898.87% year-over-year, with the annual reading at $48.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $3.0 million at Lexicon Pharmaceuticals, down from $45.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $45.0 million in Q1 2025, with the low at -$1.1 million in Q4 2023.